Brochure
Whether profiling cytokines, monitoring response to immunotherapy or identifying markers of toxicity, NULIS assays offer ultra-sensitive multiplexed assays that enable researchers to detect and quantify critical biomarkers in clinical cohorts.
Protein biomarkers enable early cancer detection, often before symptoms appear, improving the chances of successful treatment
Biomarker profiling helps tailor treatment strategies to individual patients based on their specific cancer type and protein expression patterns.
Protein biomarkers can track cancer progression and response to therapy, allowing for timely adjustments in treatment plans.
Immuno-profiling has identified early signatures associated with several adverse immune reactions to IO therapy.
Many protein biomarkers can be detected in blood, urine, or other body fluids, reducing the need for invasive biopsies.